Mass Tort Docket Financing

Mass tort docket financing is the practice of providing institutional capital to a law firm, claim aggregator, or PSC to fund the total cost of developing and resolving a large portfolio of related mass tort claims — encompassing client acquisition, case development, common benefit contributions, and operating expenses — in exchange for a return structured as a multiple of invested capital or a percentage of aggregate net recoveries. Unlike single-case financing, docket financing treats the entire portfolio as the funded asset, with individual claim variability diversified across thousands of positions and returns driven by aggregate docket performance rather than any individual outcome. Docket financing terms typically include minimum enrollment thresholds, concentration limits by injury type or state, consent rights over global settlement decisions above certain thresholds, and provisions governing the treatment of early voluntary dismissals. For institutional funders, mass tort docket financing offers scalable deployment of capital in the $50M–$500M range that is difficult to achieve through single-matter investments, but requires deep operational expertise in MDL docket management and claims administration to underwrite effectively.

Docket-level financing lets a funder diversify individual claim variability across thousands of positions, so underwriting shifts from case-by-case merits review to aggregate metrics — enrollment pace, concentration limits by injury type and state, and the firm's operational capacity to process claims at scale. Funders typically negotiate consent rights over global settlement decisions above a defined threshold and specific treatment of early voluntary dismissals, since docket-level deals depend on portfolio-wide outcomes that a single client's decisions can otherwise distort.